cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ac Immune Sa
47 own
32 watching
Current Price
$2.38
$-0.04
(-1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
326.96M
52-Week High
52-Week High
5.14000
52-Week Low
52-Week Low
1.78000
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.8528
iconMarket Capitalization326.96M
icon52-Week High5.14000
icon52-Week Low1.78000
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio9.8528
What does the Ac Immune Sa do?
AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.
Read More
News & Events about Ac Immune Sa.
Globe Newswire
9 months ago
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimers ...
Globe Newswire
11 months ago
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimers disease (AD) cohort in ABATE Phase 1b/2 trial;Further ABATE immunogenicity and safety data in higher dose AD ...
Globe Newswire
1 year ago
AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimers & Parkinsons Diseases (AD/PDTM)AC Immunes Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimers ...
Globe Newswire
1 year ago
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for ...
Globe Newswire
1 year ago
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will ...
Frequently Asked Questions
Frequently Asked Questions
What is Ac Immune Sa share price today?
plus_minus_icon
Can Indians buy Ac Immune Sa shares?
plus_minus_icon
How can I buy Ac Immune Sa shares from India?
plus_minus_icon
Can Fractional shares of Ac Immune Sa be purchased?
plus_minus_icon
What are the documents required to start investing in Ac Immune Sa stocks?
plus_minus_icon
What is today’s traded volume of Ac Immune Sa?
plus_minus_icon
What is today’s market capitalisation of Ac Immune Sa?
plus_minus_icon
What is the 52-Week High and Low Range of Ac Immune Sa?
plus_minus_icon
What percentage is Ac Immune Sa down from its 52-Week High?
plus_minus_icon
What percentage is Ac Immune Sa up from its 52-Week Low?
plus_minus_icon
Current Price
$2.38
$-0.04
(-1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00